Fig. 5: Crizotinib simultaneously suppresses TGFβ- and HGF-induced cell behaviors.

a, d A549 cells were treated with TGFβ (5 ng/mL), HGF (50 ng/mL), crizotinib (10 μM), savolitinib (10 μM), SB431542 (10 μM), or some of them for 12 h. The velocity and accumulated distance of migrated cells were quantified from 2 min interval images using the BioStation time-lapse system and ImageJ software. The data were expressed as the mean ± SEM (n = 15). *p < 0.05, ***p < 0.005. b, e After scratching, A549 cells were treated with TGFβ (5 ng/mL), HGF (50 ng/mL), crizotinib (10 μM), savolitinib (10 μM), SB431542 (10 μM), or some of them for 24 h. The wound closure area was expressed as a relative value compared to that of untreated cells, which was set to 100%. The data were expressed as the mean ± SEM (n = 10). ***p < 0.005. c, f A549 cells were treated with TGFβ (5 ng/mL), HGF (50 ng/mL), crizotinib (10 μM), savolitinib (10 μM), SB431542 (10 μM), or some of them for 24 h. A549 cells that invaded the lower chambers were counted under a phase-contrast microscope. Invasion is expressed as a relative value compared to that of untreated cells, which was set to 100%. The data are expressed as the mean ± SEM (n = 5). ***p < 0.005.